BCL-2 is a key inhibitor of the mitochondrial apoptosis pathway, and its high expression levels are associated with poor therapeutic efficacy of PTX in lung cancer patients (Maraz et al., 2011), and attenuated death in multiple myeloma cells (Gazitt et al., 1998). This evidence concerns the gene BCL2 and lung carcinoma.